Clinical Science | Novartis

Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria

Basel, June 11, 2021 — Novartis today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual Congress of the European Hematology Association (EHA). In the study (NCT03896152), treatment with 12 weeks of iptacopan monotherapy was generally…

Reimagine MedicineMedical InnovationsClinical Science
People and Culture

Going the extra mile to keep clinical trials on track during the COVID-19 pandemic

A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.

COVID-19DigitalClinical ResearchClinical TrialsClinical ScienceDrug Development
Patient Perspectives

Putting patients first

Chinweike Ukomadu thinks that notions about clinicians turning their backs on patients when transitioning to industry are outdated.

Novartis Institutes for BioMedical ResearchClinical ResearchCareersClinical TrialsClinical Science
Discovery

Women in Science: Medy Attalla

OncologyWomen in ScienceWorking at NovartisCareersClinical Science
Discovery

Women in Science: Tania Small

Meet a Senior Medical Director at Novartis who is part of our new “Women in Science” series

OncologyWorking at NovartisCareersClinical Science
Discovery

Researchers aim to beat trick play by tumors with drug combo

Biomedical ResearchDrug DiscoveryNovartis Institutes for BioMedical ResearchClinical ScienceCancer Research Institute
Discovery

Leveraging the liver’s ability to heal scarred tissue

A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.

Biomedical ResearchNovartis Institutes for BioMedical ResearchClinical ScienceDrug Design